Navigation Links
Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Company's Board of Directors
Date:2/12/2008

Huh To Step Down as COO and Head of PEGylation Business Unit

SAN CARLOS, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that Hoyoung Huh, M.D., Ph.D, is newly appointed to serve on the Board of Directors of the company. Dr. Huh will step down as Nektar's Chief Operating Officer and Head of the PEGylation Business Unit, having accepted a new leadership role as President and Chief Executive Officer at BiPar Sciences, a private biopharmaceutical company.

"Hoyoung will continue to play a strong leadership role at Nektar as a member of our Board of Directors," said Howard W. Robin, President and CEO of Nektar. "His contribution as a Board member will allow us to continue to benefit from his deep knowledge of our organization, technology platforms and development pipeline."

"The decision to step down as a COO was a difficult one," said Dr. Huh. "Nektar is positioned for great success in the future with its leading PEGylation and Pulmonary technology platforms and a deep pipeline of innovative and promising therapeutics in development. I am pleased to play an active role in the transformation of Nektar into a drug development company."

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to its board of directors and business prospects. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval, (ii) the company's or its partner's ability to obtain regulatory approval for product candidates, (iii) the success of the company's partners in sales and marketing efforts to generate from approved products and future products (if any), and (iv) the company's patent applications for its technology platforms and proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future. Important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
2. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
3. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
9. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
10. Anesiva Appoints Daniel Janney to Board of Directors
11. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... (PRWEB) September 21, 2017 , ... The 3rd ... to review the latest knowledge on these products, which are increasingly used in ... the impact of Biostimulants on Plant Nutrition, Abiotic Stresses, Plant Growth and Development, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... who enable the world’s most progressive pharma and biotech organizations to do more ... top pharma and biotech events in Q4. , DrugDev will demonstrate DrugDev Spark™, ...
(Date:9/21/2017)... S.C. (PRWEB) , ... September 21, 2017 , ... ... turned bright neon green this month, the response was swift and efficient thanks ... ( RRWQG ). RRWQG is made up of more than 50 stakeholders, including ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... today announced the election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., ... Biorez has developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):